A Phase 1 Study Of The Pharmacokinetics Of Adagrasib In Subjects With Mild, Moderate, Or Severe Hepatic Impairment Compared To Subjects With Normal Hepatic Function.
Date: 2024-03-28 Authors:C. Cilliers1, P. McCloskey1, J. Morin2, J. Tran1; 1Mirati Therapeutics, 2Innovaderm Research. Category: Other Background: This phase I study evaluated the pharmacokinetics of adagrasib in subjects with mild, moderate, or severe hepatic impairment compared to subjects with normal hepatic function. Read more on pubmed
